Costs borne by TB-affected households averted and number of households with catastrophic costs averted by adolescent/adult tuberculosis vaccines (in millions)
| Country grouping | Direct medical costs borne by TB-affected households averted | Direct non-medical costs borne by TB-affected households averted | Indirect costs borne by TB-affected households averted | Total costs borne by TB-affected households averted | Number of households with catastrophic costs averted |
| All countries | 7252 (6758–7755) | 14 987 (13 999–16 044) | 16 620 (15 574–17 858) | 38 860 (36 594–41 461) | 22.9 (21.4–24.5) |
| High-TB burden* | 5524 (5078–5956) | 12 879 (11 895–13 896) | 13 701 (12 699–14 820) | 32 103 (29 894–34 544) | 20.2 (18.7–21.8) |
| High-TB/HIV burden* | 3807 (3449–4185) | 10 719 (9803–11 698) | 11 507 (10 547–12 597) | 26 033 (23 851–28 389) | 17.3 (15.8–18.8) |
| High-MDR/RR-TB burden* | 5614 (5163–6103) | 11 676 (10 733–12 687) | 12 588 (11 605–13 676) | 29 878 (27 590–32 293) | 17.9 (16.4–19.4) |
| Income level† | |||||
| LIC | 876 (770–998) | 1686 (1533–1849) | 2842 (2494–3221) | 5405 (4812–6034) | 3.31 (3.02–3.62) |
| LMIC | 4146 (3759–4547) | 10 628 (9663–11 593) | 9449 (8627–10 315) | 24 223 (22 111–26 293) | 17.3 (15.8–18.8) |
| UMIC | 2230 (2002–2481) | 2673 (2464–2899) | 4329 (3774–4905) | 9232 (8388–10 066) | 2.25 (2.01–2.50) |
| World region | |||||
| AFR | 2126 (1933–2336) | 5084 (4684–5500) | 6597 (5968–7268) | 13 808 (12 713–15 014) | 8.52 (7.93–9.16) |
| AMR | 415 (370–461) | 530 (489–572) | 513 (472–558) | 1458 (1349–1568) | 0.30 (0.28–0.32) |
| EMR | 846 (717–988) | 1410 (1170–1651) | 2161 (1801–2557) | 4418 (3734–5169) | 2.35 (1.92–2.83) |
| EUR | 428 (364–507) | 219 (196–243) | 300 (263–341) | 947 (830–1078) | 0.15 (0.13–0.17) |
| SEAR | 1689 (1410–1997) | 5638 (4829–6510) | 4362 (3696–5071) | 11 689 (9952–13 516) | 8.94 (7.68–10.3) |
| WPR | 1748 (1546–1967) | 2105 (1905–2323) | 2686 (2368–3034) | 6539 (5907–7246) | 2.63 (2.29–3.04) |
All countries include 105 low- and middle-income countries analysed.
Values in parentheses represent equal-tailed 95% credible intervals. Total costs included patient direct medical, direct non-medical, and indirect costs (all undiscounted) over 2028–2050 in 2020 USD. Catastrophic costs are defined as instances where the total patient costs (direct medical, direct non-medical and indirect) incurred during an episode of TB disease exceeded 20% of total annual household income.
*High-TB, high-TB/HIV (HIV-associated TB), and high-MDR/RR-TB (multidrug/rifampicin-resistant TB) burden countries as defined by the WHO.
†LIC: gross national income (GNI) per capita of US$1085 or less; LMIC: GNI per capita of US$1086–4225; UMIC: GNI per capita of US$4256–13 205.26
AFR, African region; AMR, region of the Americas; EMR, Eastern Mediterranean region; EUR, European region; GDP, gross domestic product; LIC, low-income country; LMIC, lower middle-income country; SEAR, Southeast Asian region; TB, tuberculosis; UMIC, upper middle-income country; WPR, Western Pacific region.